Cognition Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview

Cognition Therapeutics

02/05/2025 14:49

Cognition Therapeutics Inc CGTX.OQ CGTX.O is expected to show no change in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Cognition Therapeutics Inc is for a loss of 11 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Cognition Therapeutics Inc is $5.00​, above​ its last closing price of $0.45. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.15
-0.14
-0.17
Missed
-19.7
Sep. 30 2024
-0.18
-0.22
-0.25
Missed
-11.1
Jun. 30 2024
-0.22
-0.24
-0.18
Beat
23.7​
Mar. 31 2024
-0.25
-0.25
-0.27
Missed
-9.5
​​Dec. 31 2023
-0.34
-0.27
Beat
21.1
Sep. 30 2023
-0.20
-0.24
-0.22
Beat
6.9​
Jun. 30 2023
-0.15
-0.19
-0.16
Beat
15.3
Mar. 31 2023
-0.18
-0.18
-0.21
Missed
-19.8

This summary was machine generated May 2 at 13:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)